Skip to main content
SpringerLink
Log in

Abatacept better option in ACPA-positive RA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Neubauer AS, et al. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept. Clinical and Experimental Rheumatology : 15 Dec 2017. Available from: URL: http://doi.org/12057 [pii]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abatacept better option in ACPA-positive RA. PharmacoEcon Outcomes News 795, 4 (2018). https://doi.org/10.1007/s40274-018-4642-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4642-7

Search

Navigation